Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives

X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disease with multisystem impact that typically begins to manifest in early childhood. Two treatment options exist: oral phosphate in combination with active vitamin D (“conventional therapy”) and a fully human monoclonal anti-FGF23 anti...

Full description

Bibliographic Details
Main Authors: Lothar Seefried, Martin Biosse Duplan, Karine Briot, Michael T. Collins, Rachel Evans, Pablo Florenzano, Neil Hawkins, Muhammad Kassim Javaid, Robin Lachmann, Leanne M. Ward
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Endocrinology
Subjects:
burosumab
X-linked hypophosphatemia
fibroblast growth factor 23
phosphate metabolism
hypophosphatemia
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1211426/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1211426/full

Similar Items